List of Excipients in Branded Drug CALCIPOTRIENE 0.005% 60 GRAM FOAM

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Trifluent Pharma LLC	CALCIPOTRIENE 0.005% 60 GRAM FOAM	calcipotriene 0.005% 60 gram foam	73352-886	.ALPHA.-TOCOPHEROL, DL-
Trifluent Pharma LLC	CALCIPOTRIENE 0.005% 60 GRAM FOAM	calcipotriene 0.005% 60 gram foam	73352-886	CETYL ALCOHOL
Trifluent Pharma LLC	CALCIPOTRIENE 0.005% 60 GRAM FOAM	calcipotriene 0.005% 60 gram foam	73352-886	EDETATE DISODIUM

Calcipotriene 0.005% 60-Gram Foam: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: September 26, 2026

Calcipotriene 0.005% foam is a prescription topical vitamin D analog for plaque psoriasis. The 60-gram aerosol format competes primarily on vehicle performance, scalp usability, tolerability, dispensing efficiency and generic price. The active ingredient is no longer the principal barrier to entry. Commercial differentiation is more likely to come from excipient selection, foam architecture, packaging, combination therapy and distribution than from new calcipotriene chemistry.

The reference product is Sorilux, approved by the FDA as calcipotriene foam, 0.005%, for plaque psoriasis in patients aged 12 years and older. A product labeled "calcipotriene 0.005% 60 gram foam" may be the reference product or an FDA-approved generic equivalent, depending on its manufacturer and NDC.

What is calcipotriene 0.005% 60-gram foam?

Calcipotriene foam contains 0.005% calcipotriene, equivalent to 50 micrograms per gram. A 60-gram can therefore contains approximately 3 milligrams of calcipotriene before accounting for residual product and manufacturing overfill.

Product characteristic	Reference information
Active ingredient	Calcipotriene
Strength	0.005%, or 50 mcg/g
Dosage form	Topical aerosol foam
Package size	60 grams
Primary indication	Plaque psoriasis
Reference product	Sorilux
FDA approval	Sorilux approved in 2010
Regulatory pathway for generics	ANDA, subject to FDA equivalence requirements
Biosimilar pathway	Not applicable
Principal commercial issue	Vehicle performance and generic substitution

The reference labeling identifies excipients including cetyl alcohol, stearyl alcohol, diethyl sebacate, polysorbate 60, propylene glycol, potassium sorbate and purified water. The aerosol package also depends on a propellant system to generate the foam during dispensing. Exact excipient identity and concentration should be assessed from the current approved label and chemistry, manufacturing and controls documentation for the specific product. (FDA, 2010; DailyMed, 2024)

What excipients are used in calcipotriene foam?

The vehicle is a water-containing emulsion or foam system designed to solubilize or disperse calcipotriene, spread rapidly over psoriatic plaques and evaporate without leaving a heavy ointment residue.

Functional role of the principal excipients

Excipient class	Representative excipient	Commercial and technical function
Fatty alcohol	Cetyl alcohol	Emulsion stabilization, consistency and skin feel
Fatty alcohol	Stearyl alcohol	Structural support and viscosity control
Emollient	Diethyl sebacate	Spreading, emolliency and reduction of greasy residue
Surfactant	Polysorbate 60	Emulsion stabilization and active distribution
Humectant or solvent	Propylene glycol	Solvency, wetting and skin hydration
Preservative	Potassium sorbate	Microbial control in the aqueous phase
Aqueous phase	Purified water	Continuous phase of the vehicle
Propellant	Hydrocarbon or other approved aerosol propellant system	Foam generation and product delivery

The formulation must balance four variables: calcipotriene chemical stability, foam collapse time, skin deposition and patient acceptability. Increasing surfactant or solvent content can improve active distribution but may increase irritation. Increasing fatty alcohol levels can strengthen foam structure but can also make the product feel waxy or slow to spread.

How does excipient strategy affect product performance?

Excipient selection controls the patient-facing attributes that distinguish foam from ointment, cream and solution dosage forms.

Foam collapse and spreadability

A foam intended for scalp and body psoriasis must collapse quickly after application while remaining sufficiently stable in the can and during dispensing. A weak foam may separate or discharge inconsistently. A foam that remains too persistent can be difficult to spread through hair or dense plaque.

The target profile is a low-residue formulation that:

• dispenses consistently throughout can life;
• collapses into a thin film after contact with skin;
• spreads over large plaque areas;
• does not require rubbing that can irritate inflamed skin; and
• remains stable across normal storage temperatures.

Skin deposition

Calcipotriene is active at a low concentration, making uniform dose delivery important. The vehicle should prevent crystallization or localized precipitation during storage and after application. Diethyl sebacate, propylene glycol and surfactant selection can influence active partitioning between the vehicle and stratum corneum.

A development program should measure:

• assay and degradation products;
• particle or crystal formation;
• delivered mass per actuation;
• content uniformity across the can;
• residual product after actuation;
• in vitro release;
• skin permeation and retention; and
• deposition on hair-bearing skin.

Irritation and tolerability

Propylene glycol, surfactants, preservatives and alcohol-containing systems can contribute to stinging or irritant dermatitis. Calcipotriene itself can cause irritation, especially when used on sensitive areas or in excessive quantities. An excipient strategy that lowers irritation can support adherence and reduce switching to lower-potency or less effective products.

Potential commercial improvements include:

• lower-irritancy surfactant systems;
• reduced solvent concentration;
• alternative preservation systems;
• controlled pH;
• lower-residue emollients; and
• propellant systems with lower cooling or irritation effects.

Any change must preserve bioequivalence or establish a clinically supportable bridge to the reference product.

What formulations are protected by calcipotriene foam patents?

The early commercial protection for calcipotriene foam focused on foamable topical composition technology, vehicle architecture and methods of treating psoriasis. Patent protection for the original formulation has largely matured or expired relative to the 2010 approval date. The commercial relevance of a particular patent depends on the product’s Orange Book listing, patent-term adjustment, pediatric extension and any later-filed patents covering formulation or manufacturing improvements.

Protection category	Relevance to calcipotriene foam
Calcipotriene composition patents	Limited relevance because the active molecule is established
Foam vehicle patents	Historically important for the reference product
Aerosol package patents	May cover valve, actuator or can configuration
Stability patents	Could protect specific excipient ratios or manufacturing controls
Method-of-use patents	May cover psoriasis treatment, body sites or dosing regimens
Combination patents	Important for calcipotriene plus betamethasone products
Manufacturing patents	May protect filling, homogenization or propellant incorporation

Patent analysis must distinguish the branded Sorilux product from calcipotriene/betamethasone foam. The latter is a separate commercial and patent category. A patent covering a combination product does not automatically block a single-agent calcipotriene foam.

What is the Orange Book status of calcipotriene foam?

Calcipotriene foam is a small-molecule drug product. The relevant generic route is an ANDA, not a biosimilar application. Orange Book analysis should focus on the reference listed drug, listed patents, regulatory exclusivity and any approved labeling differences. (FDA, 2024a)

The original Sorilux approval is more than a decade old. New applicants therefore face a conventional generic market in which the strongest barriers are likely to be:

1. formulation development and bioequivalence;
2. aerosol-device reproducibility;
3. manufacturing scale-up;
4. product liability and dermatology distribution;
5. reimbursement and pharmacy substitution; and
6. any surviving formulation or device patents.

The absence of active-ingredient exclusivity does not eliminate formulation risk. A generic sponsor can still encounter patent claims directed to a particular foam composition, canister, valve, propellant system or method of use.

When does calcipotriene foam lose exclusivity?

The key reference-product exclusivity period has already elapsed. Sorilux was approved in 2010, and its commercial protection is no longer comparable to an active new chemical entity launch. Market entry is therefore governed primarily by patent status and ANDA approval rather than by remaining NCE exclusivity.

Milestone	Approximate timing or status
Sorilux FDA approval	2010
Initial branded exclusivity period	Expired
Original formulation patent window	Largely matured relative to initial approval
Generic entry opportunity	Available subject to FDA approval and enforceable patents
Biosimilar competition	Not applicable
Current commercial protection	Product, device, manufacturing and market-access execution

The exact generic entry date depends on the ANDA sponsor, Paragraph IV certification, litigation, settlement terms and FDA approval timing.

What Paragraph IV challenges affect calcipotriene foam?

A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable or not infringed. For a mature topical aerosol product, Paragraph IV risk is usually concentrated in formulation or device patents rather than the active ingredient.

A generic sponsor may use:

• Paragraph III certification, agreeing to wait until patent expiration;
• Paragraph IV certification, challenging listed patents;
• a section viii statement, carving out a patented method of use; or
• a non-infringement strategy based on a materially different formulation.

Litigation exposure depends on whether the reference sponsor sues within the statutory period after receiving notice. A timely patent suit can trigger a 30-month stay of ANDA approval, subject to statutory exceptions. (FDA, 2024b)

Publicly available product-level information does not establish a single universal generic launch date for every 60-gram calcipotriene foam product. The launch position must be evaluated by ANDA number, manufacturer, certification type and current litigation docket.

What formulation opportunities exist for calcipotriene foam?

The most credible opportunities are incremental improvements that preserve the established indication while improving usability.

Propellant and aerosol-system reformulation

A sponsor could evaluate lower-global-warming-potential propellants, including hydrofluoroolefin systems, subject to compatibility, flammability, pressure, valve and stability requirements. The change would require substantial package-development work because propellant substitution can alter foam density, discharge rate and residual content.

Reduced-irritation vehicles

A lower-irritancy vehicle could target patients who discontinue treatment because of burning, dryness or greasy residue. The commercial value is highest if the formulation provides a measurable adherence or tolerability advantage without materially increasing manufacturing cost.

Scalp-focused delivery

Scalp psoriasis is a logical target for device and actuator innovation. Potential improvements include:

• narrow or directional actuators;
• improved delivery through hair;
• lower discharge force;
• less dripping;
• reduced residue; and
• one-handed application.

A device change may support a differentiated product, but it can also create a separate combination-product or device review burden.

Larger or multi-can packaging

A 60-gram can is practical for a standard prescription course, but larger pack sizes could reduce refill frequency for extensive disease. The commercial opportunity is constrained by labeled maximum use, stability, propellant safety and reimbursement limits.

Combination products

Calcipotriene plus betamethasone foam has a stronger commercial position than single-agent calcipotriene foam because it combines vitamin D analog activity with corticosteroid therapy. Combination products also carry greater patent, labeling and safety complexity. A single-agent formulation can compete by emphasizing steroid-free maintenance, long-term use and tolerability.

How strong is the patent estate for calcipotriene foam?

The active-ingredient patent estate is weak from an entry perspective because calcipotriene is an established molecule. The residual risk lies in formulation, device and combination-product claims.

Patent layer	Relative entry risk	Reason
Calcipotriene molecule	Low	Mature active ingredient
Single-agent foam vehicle	Low to moderate	Depends on surviving claims and listed patents
Aerosol device	Moderate	Canister, valve and actuator differences may matter
Stability and manufacturing	Moderate	Narrow claims can affect specific processes
Calcipotriene/betamethasone foam	Moderate to high	Separate combination and method-of-use estate
Clinical use patents	Low to moderate	Carve-outs may be available for some indications

A freedom-to-operate opinion should map each proposed excipient system against live U.S. claims, including continuations and patents not listed in the Orange Book. Orange Book clearance alone is insufficient for a complete formulation assessment.

Which companies are positioned in the calcipotriene foam market?

The reference-product market is associated with the Sorilux franchise and its historical sponsor and commercialization partners. Generic competition can come from manufacturers with established topical aerosol, dermatology or complex-generics capabilities.

The strongest candidates are companies that already have:

• aerosol filling capacity;
• topical dermatology sales channels;
• experience with semi-solid or foam bioequivalence;
• pharmacy benefit manager access; and
• a portfolio of psoriasis products.

A generic sponsor with no aerosol platform may face higher development costs and longer scale-up timelines than a company with existing foam manufacturing.

What commercial opportunities exist for manufacturers?

Generic single-agent launch

The lowest-risk commercial strategy is an ANDA product that matches the reference concentration, dosage form, package size and labeling. Pricing pressure will be significant once multiple suppliers enter, but the product can benefit from substitution in dermatology and specialty pharmacy channels.

Authorized generic or licensing deal

A branded manufacturer, contract development organization or generic sponsor could license:

• the reference formulation;
• a redesigned excipient system;
• an aerosol filling process;
• a device platform; or
• regional commercialization rights.

A licensing deal is most attractive when it transfers complex manufacturing knowledge rather than only the active ingredient.

Differentiated foam

A premium product could target better scalp application, lower irritation, lower residue or improved environmental profile. The product would need clinical, usability or adherence evidence because physicians and payers may treat an equivalent calcipotriene foam as interchangeable.

Combination and lifecycle management

Calcipotriene foam can support a psoriasis lifecycle strategy involving:

• steroid-free maintenance therapy;
• combination therapy with a corticosteroid;
• scalp-specific delivery;
• pediatric labeling where permitted;
• larger pack sizes; and
• geographic expansion.

Each strategy requires separate review of labeling, patent claims, clinical evidence and reimbursement.

What generic launch risks exist?

The principal risks are technical and commercial rather than active-ingredient related.

1. Aerosol reproducibility can delay approval.
2. Foam products may require more complex comparative testing than conventional creams.
3. Small differences in excipient composition can affect release and skin deposition.
4. Canister and valve suppliers can create a single-source manufacturing dependency.
5. Low-volume dermatology products may face weak forecast accuracy.
6. Reimbursement may favor the lowest-cost supplier after several ANDA approvals.
7. Combination-product competition can limit pricing power.
8. A formulation patent can create litigation even after broad exclusivity has expired.

How does calcipotriene foam compare with other dosage forms?

Dosage form	Main advantage	Main limitation
Foam	Fast spreading, useful on scalp and body, lower residue	Higher package and manufacturing complexity
Cream	Familiar and generally lower-cost	Can feel heavy and less convenient on scalp
Ointment	Strong occlusion and moisturization	Greasy, poor cosmetic acceptability
Solution	Useful for scalp or hair-bearing areas	May sting and provide less emolliency
Calcipotriene/betamethasone foam	Broader therapeutic effect	Higher safety, patent and labeling complexity

Foam occupies a premium usability position between solutions and creams. Its commercial value depends on whether patients and prescribers recognize the difference in application convenience.

Key Takeaways

• Calcipotriene 0.005% 60-gram foam is a mature small-molecule topical product, not a biologic.
• Sorilux is the principal reference product associated with the dosage form.
• The core excipients support emulsion stability, spreading, skin feel, preservation and foam generation.
• Active-ingredient exclusivity is no longer the main entry barrier.
• Formulation, aerosol-device, manufacturing and combination-product patents remain the relevant risk categories.
• Generic entry proceeds through the ANDA pathway, with Paragraph IV, Paragraph III or section viii strategies depending on live Orange Book patents.
• The best commercial opportunities are complex-generic entry, lower-irritation vehicles, scalp-directed devices, improved propellant systems and licensing of aerosol manufacturing capabilities.
• Product-level revenue for calcipotriene foam is generally not disclosed separately from broader dermatology portfolios.
• A biosimilar strategy is irrelevant because calcipotriene is a synthetic small molecule.
• The most defensible differentiation is demonstrated improvement in application, tolerability, stability or environmental performance.

Frequently Asked Questions

Is calcipotriene foam the same as calcipotriene cream?

No. The active ingredient and strength may be the same, but the excipient system, aerosol package, application characteristics and manufacturing process differ.

Can a company launch generic calcipotriene foam without developing a new clinical trial program?

An ANDA sponsor generally seeks to rely on FDA findings for the reference product, but it must establish pharmaceutical equivalence, bioequivalence and product quality under the applicable FDA requirements.

Does calcipotriene foam have biosimilar competition?

No. Biosimilars apply to biological products. Calcipotriene is a synthetic small-molecule drug and competes through generic-drug pathways.

Can a propellant change create a patentable calcipotriene foam product?

Potentially, if the resulting composition, package or performance satisfies patentability requirements and is not blocked by earlier claims. A propellant change alone does not guarantee patent protection.

Is calcipotriene foam suitable for an over-the-counter switch?

An OTC switch would require FDA review of the indication, labeling, safety profile, consumer self-selection and proposed nonprescription conditions of use. The prescription status of the existing product does not establish automatic OTC eligibility.

References

1. DailyMed. (2024). Calcipotriene aerosol foam, 0.005%: Prescribing information. U.S. National Library of Medicine.

2. U.S. Food and Drug Administration. (2010). Sorilux (calcipotriene) foam, 0.005%: FDA approval and prescribing information. Center for Drug Evaluation and Research.

3. U.S. Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.

4. U.S. Food and Drug Administration. (2024b). Guidance for industry: 180-day exclusivity when multiple ANDAs are submitted on the same day. Center for Drug Evaluation and Research.

5. U.S. Food and Drug Administration. (2024c). Orange Book: Approved drug products with therapeutic equivalence evaluations. Center for Drug Evaluation and Research.